Skip to main content

JDRF is undergoing a transformation.
We are becoming Breakthrough T1D in October.

breakthrought1d logo
Type 1 technology

Abbott, Ypsomed and CamDiab team up to offer hybrid closed loop with more affordable sensor technology

Abbott has announced that its FreeStyle Libre® 3 sensor is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab’s CamAPS FX mobile app.
JDRF logo placeholder for author profile picture
Mary-Liz McGrath 27 April 2023

A hybrid closed loop technology sensor

Abbott has announced that its FreeStyle Libre® 3 sensor is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab’s CamAPS FX mobile app.

Combined, these technologies form a hybrid closed loop system, which will deliver insulin based on real-time glucose data via an automated insulin delivery system, helping people living with type 1 diabetes improve how they manage their condition on a daily basis.

Hybrid closed loop

A hybrid closed loop system works by continuously monitoring a person’s glucose levels based on real-time readings from the glucose sensor with an algorithm in the app to calculate and deliver the right amount of insulin as needed. This removes the guesswork of insulin dosing and can improve health outcomes by helping people living with type 1 diabetes to improve their quality of life.

Draft guidance published by NICE in January recommended the use of hybrid closed loop systems, such as the one announced today by Abbott, for people with type 1 diabetes who require pump therapy.

Changing people’s lives for the better

Professor Partha S. Kar, OBE, National Specialty Advisor, Diabetes at NHS England said: “It is wonderful to see the coming together of Ypsomed’s mylife YpsoPump; CamAPX FX algorithm and Abbott’s FreeStyle Libre 3 sensor into one hybrid closed loop system – creating exciting opportunities for people living with type 1 diabetes. This type of advanced technology has the potential to change people’s lives for the better, so I’m pleased to see companies continue to innovate and bring functionality like this together, to allow for broader choice for patients and healthcare professionals.”

Hilary Nathan, Policy and Communications Director at JDRF said: “The landscape for type 1 diabetes treatment is transforming with the use of technology and hybrid closed loop systems. We are in a dynamic period of progress, and we look forward to NICE approving hybrid closed loop later this spring in England and Wales. Underpinning all product and regulatory advances lies the central principle that patients have a range of choices to ensure evidence-based treatments fit the very personalised nature of type 1 diabetes.”

Reducing the mental load

Neil Harris, General Manager of Abbott’s diabetes care business in the UK and Ireland said: “Our mission has always been to provide affordable and accessible technologies that help as many people as possible. We introduced FreeStyle Libre technology to Europe as the most affordable sensor, with the longest wear time on the market to help reduce some of the mental load that comes with managing the condition. This collaboration brings users of FreeStyle Libre 3 sensors in the UK a hybrid closed loop system that will allow them to spend even less time thinking about their diabetes and more time enjoying life.”

Sébastien Delarive, Chief Business Officer Diabetes Care at Ypsomed, said: “We are convinced that the major challenges facing society can only be solved through partnerships. We are therefore proud to expand our offering with Abbott to give the users of our mylife™ YpsoPump more freedom of choice in managing their diabetes. Our compact and easy-to-use insulin pump authorised to work with Abbott’s latest sensor and CamDiab’s adaptive hybrid closed loop app will change the lives of thousands of people affected by diabetes.”